ERBB2 and neoplasm: Additionally, pharmacological NRF2 induction by CDDO-Me significantly reduced the rate of tumour development in breast cancer-associated gene 1 (BRCA1)-deficient mice through the knockdown of ErbB2 protein expression [213], a known oncogene [214], with direct modification of ErbB2 cysteine residues [213].